Copyright ©The Author(s) 2015.
World J Ophthalmol. May 12, 2015; 5(2): 55-72
Published online May 12, 2015. doi: 10.5318/wjo.v5.i2.55
Table 5 Summary of the studies using intravitreal steroid for treatment of diabetic macular edema
AgentNumber of patientsTotal dose (daily releaseDurationMain outcomes
IVTA[86]6934 mg TA (Trivaris and triesence) (unknown)Approximately 3 moLess favorable results vs photocoagulation at 24 and 36 mo
Fluocinolone acetonide implant (ILUVIEN)[90]956180 μg (0.5 μg or 0.2 μg/d)Up to 3 yrGenerally favorable outcomes at 36 mo
Fluocinolone acetonide implant (retisert)[91]197500 μg FA (0.59 μg/d)2.5 yrEffective DME therapy at 36 mo, however high risks of cataract and glaucoma
Dexamethasone drug delivery system (ozurdex)[92]171750 μg dexamethasone (estimated approximately 6.25 μg/d)Approximately 4 moGenerally favorable outcomes at 90 d